China’s Shanghai Duoning Biotechnology Co., Ltd has entered into a licensing deal with compatriot firm BioAces (Shanghai) Life Science Co., Ltd., obtaining exclusive global rights to the latter’s cell counter products. The products in question include the CytScope PRO and CytScope MINI intelligent cell analyzers, both of which are already available on the market. No financial details of the agreement were disclosed.
Junzhen Life Science’s Product Portfolio
BioAces (Shanghai) Life Science Co., Ltd.’s product portfolio is comprehensive, featuring live cell real-time dynamic imaging, flow cytometry, and high content analysis equipment. The company is focused on the upstream process development of vaccines, monoclonal antibodies, cell and gene therapies, and other biological products. This strategic focus positions BioAces (Shanghai) Life Science Co., Ltd. as a key player in the biotechnology sector, particularly in the development of innovative tools for life science research.
Duoning Biotech’s Business Lines
Duoning Biotech, on the other hand, offers biological process solutions and laboratory products and services across two business lines. The company’s expertise in these areas complements BioAces (Shanghai) Life Science’s product portfolio, making the licensing agreement a strategic fit for both parties. By securing the global rights to BioAces (Shanghai) Life Science’s cell counter products, Duoning Biotech is poised to expand its market reach and enhance its product offerings in the global biotechnology market.-Fineline Info & Tech
